Used in pharmaceutical research as a key scaffold for developing Janus kinase (JAK) inhibitors, particularly targeting JAK1 and JAK2 involved in cytokine signaling pathways. It demonstrates potential in treating inflammatory and autoimmune diseases, such as rheumatoid arthritis and psoriasis, by modulating immune cell signaling and reducing pro-inflammatory cytokine production. The spirocyclic structure provides enhanced binding selectivity, metabolic stability, and cell permeability, aiding in the optimization of oral drug candidates with improved efficacy and minimized off-target effects. Additionally, it is explored in oncology for inhibiting tumor growth in hematological malignancies through disruption of cancer-related signaling.